Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases | Cardiology/Vascular Diseases | Family Medicine
Pulmonary Arterial Hypertension Clinical Trials
A listing of Pulmonary Arterial Hypertension medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Birmingham : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Birmingham : Cardiovascular Associates, PC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Birmingham : Cardiovascular Associates, P.C.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Birmingham : The University of Alabama at Birmingham
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Mobile : University of South Alabama Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Mobile : University of South Alabama
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Mobile : University of South Alabama
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Arizona
Phoenix : Saint Joseph's Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Phoenix : Saint Joseph's Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Phoenix : Arizona Pulmonary Specialists Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Phoenix : Pulmonary Associates Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Phoenix : Arizona Pulmonary Specialists
Remodulin® to Oral Treprostinil Transition
View More »
Phoenix : Arizona Pulmonary Specialists
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Phoenix : Arizona Pulmonary Specialists, LTD
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Tucson : The University of Arizona, Clinical and Translational Science (CATS) Research Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Tucson : University of Arizona
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Tucson : University of Arizona
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Arkansas
Little Rock : University of Arkansas for Medical Sciences Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
California
Berkeley : Alta Bates Summit Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Berkeley : Berkeley Cardiovascular Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Beverly Hills : Cedars-Sinai Heart Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fountain Valley : Allianz Research Institute, Inc. Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Fountain Valley : Alliance Medical and Research Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Fresno : University of California, San Francisco-Fresno Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Fresno : University California San Francisco
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fresno : UCSF Fresno
Ventavis® Registry Protocol
La Jolla : UCSD Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
La Jolla : UCSD Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
La Jolla : University of California San Diego Medical Center (La Jolla)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
La Jolla : UCSD Medical Center
Ventavis® Registry Protocol
Los Angeles : Ahmanson / UCLA Adult Congenital Heart Disease Center
Adult Congenital Heart Disease Registry (QuERI)
Los Angeles : Ronald Reagan UCLA Medical Center
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
Los Angeles : West Los Angeles VA Healthcare Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Los Angeles : David Geffen School of Medicine at UCLA Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Los Angeles : UCLA Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Los Angeles : University of Southern California Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Los Angeles : Cedars-Sinai Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Los Angeles : GLVA Healthcare Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Los Angeles : VA Greater LA Health Care System-UCLA
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Los Angeles : West Los Angeles VA Healthcare Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Los Angeles : University of Southern California
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Los Angeles : David Geffen School of Medicine, UCLA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Los Angeles : UCLA
Ventavis® Registry Protocol
Oakland : Berkeley Cardiovascular Medical Group
Adult Congenital Heart Disease Registry (QuERI)
Sacramento : University of California, Davis, UC Davis Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Sacramento : University of California- Davis Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
San Francisco : University of California, San Francisco
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Francisco : University of CA, San Francisco
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
San Juan Capistrano : Paloma Medical Group Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
San Juan Capistrano : Paloma Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Luis Obispo : Central Coast Chest Consultants
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Santa Barbara : Santa Barbara Cottage Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Santa Barbara : Santa Barbara Cottage Hospital
Ventavis® Registry Protocol
Stanford : Stanford University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Stanford : Stanford Hospital and Clinics
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Stockton : Pacific Sleep Disorders Center
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Torrance : UCLA Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Torrance : UCLA Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Torrance : Los Angeles Biomedical Research Institute at Harbor-UCLA Med Ctr Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Torrance : Harbor-UCLA Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Torrance : LIU Center for Pulmonary Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Torrance : Harbor-UCLA Medical Center
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Colorado
Aurora : University of Colorado Denver
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Aurora : University of Colorado Denver
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Aurora : University of Colorado Hospital
Adult Congenital Heart Disease Registry (QuERI)
Aurora : University of Colorado Denver Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Aurora : Children's Hospital Colorado Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Aurora : University of Colorado Denver Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Denver : National Jewish Medical and Research Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Denver : National Jewish Health
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Denver : Children's Hospital Denver
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Littleton : South Denver Cardiology Associates P.C. Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Littleton : South Denver Cardiology Associates PC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wheat Ridge : Robert E. Benkert, M.D.P.C. Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wheat Ridge : Western States Clinical Research, Inc.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Wheat Ridge : Western States Clinical Research
Ventavis® Registry Protocol
Connecticut
Delaware
Newark : Christiana Care Health System Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Newark : Lung Health & Sleep Enhancement Center, LLC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Newark : Lung Health & Sleep Emhancement Center, LLC
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
District of Columbia
Washington : Georgetown University Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Florida
Clearwater : CRWF
Do you have Pulmonary Hypertension?
Do you have Chronic Obstructive Pulmonary Disease (COPD)?
Tampa : CRWF, Inc.
Do you have Pulmonary Hypertension?
Do you have Chronic Obstructive Pulmonary Disease (COPD)?
View More »
Brandon : Bay Area Cardiology Assoc., P.A.
Adult Congenital Heart Disease Registry (QuERI)
Brandon : Bay Area Cardiology Research, P.A. Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Brandon : Bay Area Cardiology Associates, PA
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Clearwater : Bay Area Chest Physicians Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Clearwater : St. Francis Sleep Allergy & Lung
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fort Lauderdale : Broward Pulmonary and Sleep Specialists Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Gainesville : University of Florida, Shands Hospital
Adult Congenital Heart Disease Registry (QuERI)
Gainesville : University of Florida
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Gainesville : University of Florida
Ventavis® Registry Protocol
Hollywood : Memorial Regional Hospital
Adult Congenital Heart Disease Registry (QuERI)
Jacksonville : University of Florida, Jacksonville
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
Jacksonville : University of Florida College of Medicine Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Jacksonville : Mayo Clinic Jacksonville
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Jacksonville : Pulmonary and Critical Care Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Jacksonville : University of Florida College of Medicine Jacksonville
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Jacksonville :
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Miami : Miami Center for Cardiovascular Disease
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Miami Beach : Mount Sinai Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Miramar Beach : Sacred Heart Medical Group
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Orlando : Central Florida Pulmonary Group, PA Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Orlando : Central Florida Pulmonary Group, P.A.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Orlando : Orlando Heart Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Orlando : Orlando Heart Center
Ventavis® Registry Protocol
Orlando : Central Florida Pulmonary Group
Ventavis® Registry Protocol
Pensacola : Cardiology Consultants
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Pensacola : Pensacola Lung Group
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Sarasota : Lung Associates of Sarasota Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Tampa : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Weston : Cleveland Clinic Florida Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Weston : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Weston : Cleveland Clinic Florida Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Weston : Cleveland Clinic Florida
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Weston : Cleveland Cliic Florida
Ventavis® Registry Protocol
Georgia
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Atlanta : Emory University Hospital-Emory Clinic Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Atlanta : Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Atlanta : Emory University School of Medicine
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Augusta : Georgia Health Sciences University
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Augusta : Doctors Hospital of Augusta
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Austell : Georgia Clinical Research
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Austell : Georgia Lung Associates, PC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Duluth : Duluth Biomedical Research
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Lawrenceville : Gwinnett Consultants in Cardiology
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Roswell : Atlanta Cardiology Consultants
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Hawaii
Aiea : Queens Medical Center - Honolulu
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Illinois
Chicago : Rush University Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Chicago : University of Chicago
Assessmet of Patients With PAH Right Ventricular Volume
Chicago : Northwestern University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Chicago : University of Chicago
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Chicago : University of Illinois at Chicago Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Chicago : Northwestern University
Ranolazine and Pulmonary Hypertension
Chicago : Northwestern Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Chicago : University of Illinois at Chicago
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Chicago : Rush University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Gurnee : Dor Heart and Vascular Clinic
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Maywood : Loyola University of Chicago
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Oakbrook Terrace : Midwest Heart Foundation
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Peoria : Methodist Medical Center of Illinois
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Indiana
Carmel : Clarian North Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Carmel : Indiana University Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Iowa
Iowa City : University of Iowa Hospitals & Clinics Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Iowa City : University of Iowa Hospitals & Clinics Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Iowa City : University of Iowa Hospitals & Clinics
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Iowa City : University of Iowa
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Iowa City : Mercy Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Kansas
Kansas City : The University of Kansas Hospital
Adult Congenital Heart Disease Registry (QuERI)
Kansas City : University of Kansas Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Kansas City : University of Kansas Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Kansas City : The University of Kansas Medical Center
Ventavis® Registry Protocol
Kentucky
Lexington : University of Kentucky Gill Heart Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Louisville : Kentuckiana Pulmonary Associates
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Louisville : Kentuckiana Pulmonary Associates
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Louisville : University of Louisville, Pediatric Cardiology
Adult Congenital Heart Disease Registry (QuERI)
Louisville : Kentuckiana Pulmonary Associates Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Louisville : Kentuckiana Pulmonary Associates Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Louisville : Kentuckiana Pulmonary Associates
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Louisville : Kentuckiana Pulmonary Associates
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Louisville : Kentuckiana Pulmonary Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Louisville : Kentuckiana Pulmonary Associates
Ventavis® Registry Protocol
Louisiana
New Orleans : LSUHSC-New Orleans Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
New Orleans : LSU Health Science Center - New Orleans
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
New Orleans : Ochsner Clinic
Ventavis® Registry Protocol
Maine
Portland : Pediatric Cardiology Associates
Adult Congenital Heart Disease Registry (QuERI)
Portland : Maine Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Maryland
Baltimore : Johns Hopkins University
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Baltimore : University of Maryland Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Baltimore : University of Maryland Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Baltimore : University of Maryland
Adult Congenital Heart Disease Registry (QuERI)
Baltimore : University of Maryland Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Baltimore : John Hopkins University Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Baltimore : University of Maryland Medical Centre Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Baltimore : Johns Hopkins University Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Baltimore : Johns Hopkins University School of Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Baltimore : Johns Hopkins University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Baltimore : University of Maryland
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Baltimore : University of Maryland School of Medicine
Ventavis® Registry Protocol
Massachusetts
Boston : Boston University School of Medicine
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Boston : Tufts Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Boston : Brigham and Women's Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Boston : Tufts Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Boston : Brigham and Women's Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
View More »
Boston : Boston University School of Medicine
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Boston : Center for Adults with Congenital Heart Disease
Adult Congenital Heart Disease Registry (QuERI)
Boston : Brigham and Women's Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Boston : Massachusetts General Hospital Updated
Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan
Boston : Tufts Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Boston : Boston University Medical Center/Boston University School of Medicine Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Boston : Tufts Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Boston : Boston University Medical School
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Boston : Massachusetts General Hospital - Pulmonary Critical Care Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Boston : Tufts Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Boston : Boston University School of Medicine / Boston University Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Boston : Tufts - New England Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Boston : Brigham and Women's Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Worcester : University of Massachussetts Memorial Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Michigan
Ann Arbor : University of Michigan Adult Congenital Program
Adult Congenital Heart Disease Registry (QuERI)
Ann Arbor : University of Michigan Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Ann Arbor : University of Michigan-Scleroderma Program
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Ann Arbor : University of Michigan Pulmonary Hypertension Program Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Ann Arbor : University of Michigan
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Detroit : Wayne State University, Detroit Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Detroit : Henry Ford Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Detroit : Henry Ford Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Grand Rapids : Spectrum Health Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Milwaukee : Madison Medical Affiliates
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Troy : William Beaumont Hospital - Troy Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Troy : Beaumont Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Troy : William Beaumont Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Minnesota
Minneapolis : University of Minnesota Physicians Heart Fairview
Adult Congenital Heart Disease Registry (QuERI)
Minneapolis : University of Minnesota, Cardiovascular Division Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Minneapolis : Hennepin County Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Minneapolis : University of Minnesota
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Rochester : Mayo Clinic
Assessmet of Patients With PAH Right Ventricular Volume
View More »
Rochester : Mayo Clinic Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Rochester : Mayo Clinic
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Missouri
Kansas City : Mid-America Heart Institute / St Luke's Hospital / Saint Luke's Cardiovascular Consultants
Adult Congenital Heart Disease Registry (QuERI)
St. Louis : Washington University School of Medicine
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
St. Louis : Washington University School of Medicine
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
St. Louis : Barnes-Jewish Hospital/Washington University School of Medicine
Adult Congenital Heart Disease Registry (QuERI)
St. Louis : Washington University School of Medicine Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
St. Louis : Washington University School of Medicine
Remodulin® to Oral Treprostinil Transition
St. Louis : Washington University School of Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
St. Louis : Washington University School of Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
St. Louis : St. Louis University
Ventavis® Registry Protocol
Nebraska
Lincoln : Nebraska Pulmonary Specialties, LLC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Lincoln : Nebraska Pulmonary Specialties, LLC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Lincoln : Nebraska Pulmonary Specialties
Ventavis® Registry Protocol
Omaha : Creighton University Medical Centre - Pulmonary, Critical Care and Sleep Medicine Division Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Omaha : University of Nebraska Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Nevada
Las Vegas : Childrens Heart Center Nevada
Adult Congenital Heart Disease Registry (QuERI)
Las Vegas : The Lung Center of Nevada Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Reno : Sierra Nevada Cardiology Associates
Ventavis® Registry Protocol
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Lebanon : Dartmouth-Hitchcock Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
New Jersey
Bloomfield : Michael Schwarz, MDFACC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Hackensack : Hackensack University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New Brunswick : University of Medicine and Dentistry of New Jersey
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New Brunswick : UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Newark : Barnabas Health Newark Beth Israel Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Newark : Pulmonary Hypertension & Lung Transplant Program Newark Beth Israel Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Newark : Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Newark : University of Medicine and Dentistry of New Jersey
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Newark : Newark Beth Israel Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Newark : Newark Beth Israel Medical Center
Ventavis® Registry Protocol
Union : AZ Perfection Clinical
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
New York
Lake Success : Biomedical Research Alliance of New York
Scleroderma and Pulmonary Hypertension (PHT) - Adults
New Hyde Park : Biomedical Research Alliance of New York
Pulmonary Arterial Hypertension (PAH) - Adults
View More »
Albany : Capital District Pediatric Cardiology Associates
Adult Congenital Heart Disease Registry (QuERI)
Albany : Center for Rheumatology
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Bronx : Montefiore Medical Center - Moses Division;The University Hospital for Albert Einstein College of Medicine
Adult Congenital Heart Disease Registry (QuERI)
Bronx : Montefiore Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Bronx : Montefiore Medical Center, Weiler Division
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Bronx : Montefiore Medical Center
Ventavis® Registry Protocol
Buffalo : Kaleida Health/Buffalo General Hospital
Ventavis® Registry Protocol
Cooperstown : Bassett Healthcare Network - Bassett Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Islandia : SUNY Stony Brook University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Mineola : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Mineola : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Mineola : Winthrop Pulmonary Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Mineola : Winthrop University Hospital
Ventavis® Registry Protocol
New Hyde Park : North Shore Long Island Jewish Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New Hyde Park : North Shore - LIJ Health System Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
New Hyde Park : North Shore - Long Island Jewish Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New Hyde Park : North Shore University - LIJ Medical Center
Ventavis® Registry Protocol
New York : Mount Sinai Pulmonary Hypertension Program
Adult Congenital Heart Disease Registry (QuERI)
New York : Schneeweiss Adult Congenital Heart Center - Columbia University Medical Center
Adult Congenital Heart Disease Registry (QuERI)
New York : Weill Cornell Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
New York : Beth Israel Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
New York : Cornell University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New York : Hospital for Special Surgery
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New York : Beth Israel Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
New York : Columbia University Medical Center, Pediatric Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
New York : Columbia University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New York : St. Luke's-Roosevelt Hospital Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New York : Beth Israel Medical Center
Ventavis® Registry Protocol
Rochester : University of Rochester
Remodulin® to Oral Treprostinil Transition
Rochester : Mary M Parkes Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Rochester : Mary M. Parkes Asthma Center, University of Rochester
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Syracuse : Pulmonary Health Physicians
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Syracuse : Pulmonary Health Physicians
Ventavis® Registry Protocol
North Carolina
Charlotte : American Health Research
6 week Study for Patients with Pulmonary Hypertension Associated with COPD
View More »
Asheville : Asheville Cardiology Associates
Adult Congenital Heart Disease Registry (QuERI)
Chapel Hill : University of North Carolina at Chapel Hill
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Durham : Duke University Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Durham : Duke University Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Durham : Duke University Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Durham : Duke University Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Durham : Duke University Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Greenville : East Carolina Heart Institute of East Carolina University
Adult Congenital Heart Disease Registry (QuERI)
Greenville : East Carolina University Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Pinehurst : Pinehurst Medical Clinic
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Winston-Salem : Wake Forest University Phyisicans Clinic/Pulmonary Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Winston-Salem : Wake Forest University Health Sciences
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Ohio
Akron : Akron General Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Cincinnati : University of Cincinnati
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Cincinnati : University of Cincinnati
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Cincinnati : Cincinnati Adolescent and Adult Congenital Heart Disease Program, The Heart Institute at Cincinnati Childrens Hospital Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Cincinnati : UC Health/University of Cincinnati Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Cincinnati : University of Cincinnati Pulmonary Critical Care & Sleep Medicine Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Cincinnati : The Christ Hospital Heart & Vascular Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Cincinnati : The Lindner Clinical Trial Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Cincinnati : University of Cincinnati
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cincinnati : University of Cincinnati
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Cincinnati : University of Cincinnati
Ventavis® Registry Protocol
Cleveland : The Cleveland Clinic Adult Congenital Heart Disease Center
Adult Congenital Heart Disease Registry (QuERI)
Cleveland : Cleveland Clinic
Assessmet of Patients With PAH Right Ventricular Volume
Cleveland : University Hospitals Case Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Cleveland : Cleveland Clinic Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Cleveland : University Hospitals Case Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Cleveland : University Hospitals Case Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Cleveland : Cleveland Clinic
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cleveland : University Hospitals of Cleveland
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Columbus : The Ohio State University Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Columbus : The Ohio State University Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Columbus : The Research Institute at Nationwide Children's Hospital
Adult Congenital Heart Disease Registry (QuERI)
Columbus : Ohio State University Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Columbus : Ohio State University Martha Morehouse Medical Pavillion Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Columbus : The Ohio State University Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Columbus : Ohio State University, Martha Morehouse Medical Plaza
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Columbus : Davis Heart and Lung Research Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Columbus : The Ohio State University Medical Center
Ventavis® Registry Protocol
Dayton : Dayton Respiratory Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Dayton : Midwest Pulmonary & Sleep Research
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Fairfield : Mercy Fairfield Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Middleburg Heights : Southwest General Health Center
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Toledo : University of Toledo Health Sciences Campus Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Oklahoma
Oklahoma City : South Oklahoma Heart Research LLC Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Oregon
Bend : Heart Center Cardiology Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Portland : Legacy Medical Group - Pulmonary Clinic Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Portland : Oregon Pulmonary Associates, PC
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Portland : OHSU-Oregon Health and Science University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Portland : Legacy Pulmonary Northwest
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Portland : Oregon Clinic, PC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pennsylvania
Doylestown : Central Bucks Specialists
Adult Congenital Heart Disease Registry (QuERI)
Doylestown : Central Bucks Specialists - The Pavilion at Doylestown Hospital Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Doylestown : Central Bucks Specialists
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Hershey : The Pennsylvania State University College of Medicine and The Pennsylvania State Milton S. Herhsey Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Hershey : Penn State Milton S. Hershey Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Langhorne : Institute for Respiratory and Sleep Medicine Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Philadelphia : Temple University Hospital
Adult Congenital Heart Disease Registry (QuERI)
Philadelphia : Temple University Hospital Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Philadelphia : Pulmonary Vascular Disease Program, Penn Presbyterian Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : Pulmonary Hypertension Program, Cardiology, Children's Hospial of Philadelphia Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : Penn Presbyterian Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Philadelphia : Thomas Jefferson University Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Philadelphia : University of Pennsylvania Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : Thomas Jefferson University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : Temple University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : Children's Hospital of Philadelphia
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pittsburgh : University of Pittsburgh Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Pittsburgh : University of Pittsburgh Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Pittsburgh : Allegheny General Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Pittsburgh : Allegheny Singer Research Institute/Allegheny General Hospital Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Pittsburgh : University of Pittsburgh
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Pittsburgh : University of Pittsburgh Medical Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Pittsburgh : Allegheny General Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Pittsburgh : University of Pittsburgh Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pittsburgh : Allegheny General Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Wyomissing : Respiratory Specialists Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wyomissing : Berks Schuylkill Respiratory Specialists, Ltd.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
York : Wellspan Lung, Sleep and Critical Care Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Rhode Island
Providence : Rhode Island Hospital Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Providence : Rhode Island Hospital Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Providence : Rhode Island Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
South Carolina
Charleston : Medical University of South Carolina
Adult Congenital Heart Disease Registry (QuERI)
Charleston : Medical University of South Carolina
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Lexington : Lexington Pulmonary and Critical Care
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
South Dakota
Sioux Falls : Sioux Falls Cardiovascular PC Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Sioux Falls : Sioux Falls Cardiovascular PC Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Tennessee
Chattanooga : MD Total Care, PLLC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Knoxville : Statcare Pulmonary Consultants Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Knoxville : Summit Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Nashville : Vanderbilt University Medical Center
Adult Congenital Heart Disease Registry (QuERI)
Nashville : Vanderbilt Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Nashville : Vanderbilt University Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Nashville : Vanderbilt University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Texas
Dallas : University of Texas Southwestern Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Dallas : University of Texas Southwestern Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Dallas : University of Texas Southwestern Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Dallas : UT Southwestern Medical Center at Dallas
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Dallas : UT Southwestern Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
View More »
Dallas : UT Southwestern Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Dallas : UT Southwestern Medical Center
Ventavis® Registry Protocol
El Paso : El Paso Respiratory and Sleep Consultants Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Houston : Baylor College of Medicine
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Houston : Texas Children's Hospital/Baylor College of Medicine
Adult Congenital Heart Disease Registry (QuERI)
Houston : Baylor
Assessmet of Patients With PAH Right Ventricular Volume
Houston : Baylor College of Medicine Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Houston : The University of Texas Health Science Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Houston : UT Health - University of Texas Houston Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : Baylor College of Medicine Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : Baylor College of Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Houston : University of Texas-Houston Health Center Department of Pulmonary & Critical Care
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Houston : Baylor College of Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Houston : Baylor College of Medicine
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : Texas Children's Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : University of Texas Health Science Center at Houston
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : Baylore College of Medicine
Ventavis® Registry Protocol
San Antonio : Methodist Healthcare System of San Antonio
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Antonio : University of Texas Health Science Center at San Antonio
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Antonio : Pulmonary Consultants of San Antonio, PA
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Utah
Murray : Intermountain Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Provo : Central Utah Clinic
Ventavis® Registry Protocol
Salt Lake City : University of Utah
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Salt Lake City : University of Utah
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Virginia
Charlottesville : University of Virginia Health Systems
Adult Congenital Heart Disease Registry (QuERI)
Charlottesville : The Rector and Visitors of the University of Virginia
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Falls Church : Inova Fairfax Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Falls Church : Inova Fairfax Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Falls Church : IHVI, Advanced Lung Disease and Transplant Clinic Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Falls Church : Inova Fairfax Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Lynchburg : The Cardiovascular Group Central
Adult Congenital Heart Disease Registry (QuERI)
Norfolk : Children's Specialty Group PLLC, Children's Hospital of the King's Daughters
Adult Congenital Heart Disease Registry (QuERI)
Norfolk : Sentara Medical Group Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Norfolk : Sentara Cardiovascular Research Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Norfolk : Sentara Cardiovascular Research Institute
Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects With Pulmonary Arterial Hypertension
Norfolk : Sentara Norfolk General Hospital
Ventavis® Registry Protocol
Richmond : Virginia Commonwealth University
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
Washington
Puyallup : Cardiac Study Center Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Seattle : University of Washington
Adult Congenital Heart Disease Registry (QuERI)
Spokane : Spokane Respiratory Consultants
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
West Virginia
Wisconsin
Madison : University of Wisconsin Hospital-Department of Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Milwaukee : Aurora St. Luke's Medical Center
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Milwaukee : Aurora St. Luke's Medical Center
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Milwaukee : Aurora St. Luke's Medical Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Milwaukee : The Medical College of Wisconsin
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
View More »
Milwaukee : St. Luke's Medical Center
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Milwaukee : Froedtert Hospital - Medical College of Wisconsin
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Milwaukee : Aurora St. Luke's Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Milwaukee : Aurora Health Care
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Milwaukee : St. Luke's Medical Center
Ventavis® Registry Protocol
Argentina
Buenos Aires : Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Buenos Aires : Sanatorio Otamendi y Miroli S.A.
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Buenos Aires : Hospital Britanico-Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Buenos Aires : Sanatorio San Jose
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Cordoba : Hospital Privado Centro Medico de Cordoba S.A.
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Corrientes : Instituto De Cardiologia de Corrientes
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Australia
Adelaide : Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Bedford Park : Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Brisbane : The Prince Charles Hospital
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
Chermside : The Prince Charles Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Chermside : The Prince Charles Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
View More »
Chermside : Prince Charles Hospital Lung Transplant, Thoracic Department
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Darlinghurst : St. Vincent's Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Darlinghurst : St. Vincent's Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Darlinghurst : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Darlinghurst : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Darlinghurst : St. Vincent's Hospital / Heart and Lung Transplant Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Fitzroy : St Vincent's Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Hobart : Royal Hobart Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Hobart : Royal Hobart Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Hobart : Royal Hobart Hospital, Centre for Clinical Research
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Melbourne : The Alfred Hospital
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Melbourne : The Alfred Hospital
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
New Lambton : John Hunter Hospital Autoimmune Resource and Research Centre
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Parkville : Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Perth : Royal Perth Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Austria
Graz : Medizinische Universität Graz
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Vienna : Medical University of Vienna and AKH Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Belarus
Minsk : Minsk City Hospital No. 9
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Minsk : The Republican Scientific-Practical Center "Cardiology"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Minsk : Minsk Regional Clinical Hospital of the Red Banner of Labour
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Belgium
Brussels : Ulb Erasme, Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Bruxelles : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Leuven : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Leuven : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Leuven : University Hospital Gasthuisberg - Pneumologie
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Canada
Calgary : Peter Lougheed Center Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Edmonton : ABACUS - University of Alberta Hospitals Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Edmonton : University of Alberta Hospital - Children's Centre
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
London : London Health Sciences Centre Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
View More »
Montreal : Hopital General Juif (Jewish General Hospital)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Ottawa : University of Ottawa Heart Institute
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Quebec City : Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Tononto : Toronto General Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Toronto : University Health Network - Toronto General Hospital Updated
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Toronto : University Health Network
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Vancouver : Vancouver General Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Winnipeg : Health Sciences Centre
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Chile
Santiago : Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Santiago : Clinica Tabancura- Cardiology Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Santiago : Instituto Nacional del Torax Teaching Dept
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Colombia
Bogota : Fundacion Cardio Infantil
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Bogota : Fundacion Clinica Shaio
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Czech Republic
Praha 2 : Gen Faculty Hosp Prague Cardiology Clin
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Denmark
Arhus : Aarhus University Hospital , Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Copenhagen : Rigshospitalet, Hjertemedicinsk klinik - Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
France
Bron cedex : Hosp Pradel Lyon - Dpt Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Caen Cedex : Hosp Cote de Nacre - Dpt Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Clamart : Hosp A. Beclere - Dept Pulmo & Resp Intensive Care
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Lille : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Lille Cedex : Hosp Huriez - Dpt Internal Medecine
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Strasbourg : Hosp Civil - Dpt Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Toulouse Cedex 9 : Hosp Larrey - Dpt Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Germany
Berlin : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Berlin : DRK Kliniken Köpenick
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Coburg : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Dresden : Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Essen : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
View More »
Giessen : "Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Greifswald : Universität Greifswald / Klinik für Innere Medizin B
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Hamburg : Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf
Endothelial Function in Patients With Pulmonary Arterial Hypertension
Hannover : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Hannover : Medizinische Hochschule Hannover / Klinik für Pneumologie
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Heidelberg : Thoraxklinik am Universitätsklinikum Heidelberg
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Homburg : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Köln : "Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Leipzig : Praxis für Pneumologie und Allergologie
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Löwenstein : Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Nuernberg : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Regensburg : Universitätsklinkum Regensburg / Innere Medizin II
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Wuerzburg : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Greece
Athens : Onasseio Cardiosurgical Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Haidari : Pfizer Investigational Site Updated
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Thessaloniki : University Hospital of Ahepa
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Hungary
Budapest : Semmelweis Karlocai
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Budapest : Gottsegen Gyorgy Hungarian
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Budapest : Semmelweis University
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Budapest : Gottsegen Gyorgy Hungarian
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Budapest : "Semmelweis Egyetem, Pulmonológiai Klinika"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Budapest : "Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Debrecen : University of Debrecen
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Debrecen : University of Debrecen
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Debrecen : Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Pécs : "Pécsi Tudományegyetem Klinikai Központ,
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Szeged : University of Szeged
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Szeged : University of Szeged
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Szeged : "Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
India
Ahmedabad : Sanjivani Hospitals - Department of Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Chennai : Apollo Hospitals, Chennai
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Chennai : Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Hyderabad : CARE Hospitals Nampally, Cardiology Dep. Hyderabad
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
New Delhi : Apollo Indraprastha Hospitals
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Ireland
Dublin : Mater Miscordiae University Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Israel
Haifa : Department of Cardiology, Rambam Medical Center
Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)
Haifa : Carmel Medical Center, Pulmonary Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Jerusalem : Pulmonology Institute, Hadassah University Hospital at Ein Karem
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Petach Tikvah : Rabin Medical Centre - Pulmonology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Rehovot : Kaplan Medical - Pulmonary Institute
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Tel-Hashomer : The Chaim Sheba Med Ctr -Pulmonology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Italy
Japan
Azumino : Nagano Children's Hospital Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Fukuoka : Fukuoka Children's Hospital & Medical Center for Infectious Diseases Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Shinjyuku-ku : Tokyo Women's Medical University Hospital Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Shizuoka : Shizuoka Children's Hospital Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Suita : Osaka University Hospital Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
View More »
Tokyo : Toho University Omori Medical Center Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Yokohama : Kanagawa Children's Medical Center Updated
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Korea, Republic of
Incheon : Gil Medical Centre
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Seoul : Samsung Medical Center
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Seoul : Seoul National University Hospital
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Seoul : Samsung Medical Center, Division of Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Seoul : Yonsei University Health System Dept of Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Seoul : Seoul Nathional University Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Seoul : "The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Special City of Seoul : Severance Hospital, Yonsei University Health System
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Lithuania
Vilnius : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Vilnius : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Malaysia
Kuala Lumpur : Institut Jantung Negara (National Heart Institute)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Mexico
Netherlands
Amsterdam : VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Maastricht : Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Nieuwegein : St. Antonius Ziekenhuis afdeling Longziekten
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Rotterdam : Erasmus Medisch Centrum Rotterdam afdeling longziekten
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Peru
Poland
Gdansk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Gdańsk : "Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Krakow : "Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Łódź : "Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Many Locations :
Efficacy of Ventavis Used in Real-life Setting.
View More »
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Warszawa : "Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Warzawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Puerto Rico
Guaynabo : CardioPulmonary Research Center
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
San Juan : PAH Clinic CPR at Auxilio Mutuo Updated
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Romania
Russian Federation
Barnaul : Municipal Medical Institution City Hospital #5
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Ekaterinburg : Regional Clinical Hospital # 1
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Kemerovo : Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Moscow : State Institution, "Institute fo Rheumatology of RAMS"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Moscow : Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
View More »
Moscow : The Institution of the Clinical Cardiology named after A. L. Myaskinov
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Novosibirsk : State Institution "Scientific Research Institute of clinical and experimental Lymphology of RAMS, Siberian branch"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
St Petersburg : V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Tomsk : Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Tomsk : Tomsk Regional Clinical Hospital/ Pulmonology Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Serbia
Belgrade : "Kliničko-bolnički centar Zemun, Kardiološko odeljenje"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Belgrade : "Klinički Centar Srbije, Klinika za pulmologiju"
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Singapore
Singapore : National Heart Centre (NHC) Singapore
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Slovakia
Spain
Barcelona : Clinic-Barcelona
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Barcelona : Hosp Vall D'Hebron - Barcelona - Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Madrid : Hospital 12 Octubre
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Many Locations :
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Sweden
Goteborg : Sahlgrenska Universitetssjukhuset, Kardiologi
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Linköping : Linköping University Hospital, Cardiology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Umea : Umeå University Hospital, Cardiology (Umeå)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Uppsala : Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Switzerland
Basel : University Hospital Basel Division of Pneumology
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Bern : Universitätsspital Bern, Clinic for Pneumology (Inselspital)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Genève 14 : HUG Hôpitaux Universitaires de Genève; Pneumology, PAH
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
St. Gallen : Kantonsspital St. Gallen Klinik für Pneumologie
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Taiwan
Kaohsiung : Kaohsiung Veterans General Hospital (KVGH)
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Taipei : National Taiwan University Hospital / Department of Surgery
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Thailand
Turkey
Adana : Çukurova Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Istanbul : Marmara Üniversitesi Tip Fakultesi Kardiyoloji Anabilim Dali
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Istanbul : Istanbul Üniversitesi Kardiyoloji Enstitisü
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
İzmir : Dokuz Eylül Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Ukraine
United Kingdom
Bloomsbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Glasgow : Golden Jubilee - Pulm Vascular Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
London : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
London : Royal Free & Ucms Rheumatology Unit
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
London : Hammersmith
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
